Abiogen Pharma SpA, of Pisa, Italy, said it granted Lee's Pharmaceutical Ltd., of Hong Kong, the license, distribution and marketing of Attila (neridronic acid) throughout China, Hong Kong, Macau and Taiwan for the two orphan/rare disease indications osteogenesis imperfecta and complex regional pain syndrome.